GlassScriptPhysician profile
Nabil J Azar
NPI 1972644391
$164,185.55
in general payments reported to CMS, 2019-2025
23 companies · $7,931 in 2025
The $7,931 reported for 2025 was more than what 88% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $47K · 2021: $26K · 2022: $37K · 2023: $19K · 2024: $9,225 · 2025: $7,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $5,168 · Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,565.00 |
| Travel and Lodging | $5,167.79 |
| Food and Beverage | $2,097.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $65,804.85 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $60,879.66 | 2020-2022 | |
| Aquestive Therapeutics, INC. | $23,711.11 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $12,294.59 | 2019-2022 | |
| Ucb, INC. | $395.23 | 2022-2025 | Fintepla |
| Dexcom, INC. | $151.19 | 2021-2024 | Dexcom G6 Transmitter |
| Grt US Holding, INC. | $123.33 | 2022 | |
| Eisai INC. | $110.24 | 2019 | |
| Pyros Pharmaceuticals, INC. | $106.57 | 2024 | Vigpoder |
| Amgen INC. | $97.27 | 2019-2025 | Uplizna |
| Pfizer INC. | $96.18 | 2019-2025 | |
| Boston Scientific Corporation | $89.04 | 2021-2024 | |
| Lundbeck LLC | $76.67 | 2023-2025 | Vyepti, Rexulti |
| Neuropace, INC. | $49.65 | 2019 | |
| Biogen, INC. | $42.11 | 2021-2024 | Skyclarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.28 | 2019-2020 | |
| Averitas Pharma INC. | $29.28 | 2025 | Qutenza |
| Greenwich Biosciences, INC. | $23.82 | 2019 | |
| Abbott Laboratories | $17.67 | 2025 | Freestyle Libre 3 |
| Scilex Pharmaceuticals INC. | $15.12 | 2019 | |
| Argenx US, INC. | $13.05 | 2022 | |
| Zogenix INC. | $12.12 | 2021 | |
| Celgene Corporation | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.